Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein
Case ID:
TAB-2777
Web Published:
12/6/2022
This technology comprises sulfated recombinant gp120 proteins and peptides. Also included are methods for producing sulfated recombinant gp120 proteins. The focus of this technology is on sulfation of two tyrosines in the V2 loop of the HIV major envelope glycoprotein, gp120, which increase the stability of gp120 and promote the synthesis of gp120 protein in its native "closed" conformation. Gp120 in its native form is highly sulfated; however, recombinant gp120 produced for vaccines or structural analyses typically display low levels of V2 tyrosine sulfation. Sulfation of the V2 loop results in increased binding to trimer-recognizing anti-HIV antibodies specific to the V2 loop region of gp120 (PG9, PG16, CH01, PGT145) and decreased binding of CD4. The sulfation of recombinant gp120 is accomplished by over expression of a tyrosyl sulfotransferase in the producing cell line. Preliminary experiments indicate the recombinant sulfated gp120 proteins can be used to elicit the formation of HIV neutralizing antibodies in immunized animals.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Recombinant_Sulfated_HIV_Env elope_Protein_and_Methods_for_Making_Protein
Keywords:
BETWEEN
CD4
DB4XXX
DBXXXX
DC5XXX
DCXXXX
DXXXXX
Envelope
gp120
HIV
INHIBIT
INTERACTION
Mimics
Peptide
Protein
RECEPTOR
That
V2-loop
VLXXXX
WIXXXX
WJXXXX
WKXXXX
YAXXXX
YBXXXX
YCXXXX
YFXXXX
Bookmark this page
Download as PDF
For Information, Contact:
Chris Kornak
Lead Technology Transfer and Patent Specialist
NIH Technology Transfer
chris.kornak@nih.gov